A5071349192- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- MicroRNA in disease regulation
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Reproductive System and Pregnancy
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- T-cell and B-cell Immunology
- Extracellular vesicles in disease
- Vitamin D Research Studies
- Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Molecular Biology Techniques and Applications
LabCorp (United States)
2023-2025
IQE (United Kingdom)
2018-2024
University of Missouri–Kansas City
2023
Mercy Research
2023
Ibero American University
2020
Roswell Park Comprehensive Cancer Center
2006-2016
Background : Global DNA hypomethylation may result in chromosomal instability and oncogene activation, as a surrogate of systemic methylation activity, be associated with breast cancer risk. Methods Samples data were obtained from women incident early-stage (I–IIIa) who free, frequency matched on age race. In preliminary analyses, genomic leukocyte was determined by measuring 5-methyldeoxycytosine (5-mdC), well analysis the LINE-1-repetitive element. Further analyses used only 5-mdC levels....
<h3>Background</h3> Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 mutational burden show incomplete predictive performance. The validity utility complex been studied in <h3>Methods</h3> Cutaneous metastatic melanoma at eight institutions were evaluated for expression, CD8<sup>+</sup> T-cell infiltration pattern, burden, 394 immune transcript expression. IHC assessed association...
<h3>Background</h3> Resistance to immune checkpoint inhibitors (ICIs) has been linked local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity ICIs in non-small cell lung cancer (NSCLC) patients. <h3>Methods</h3> Tumor specimens from 120 NSCLC patients 10 institutions were evaluated for by immunohistochemistry, and global proliferative profile targeted...
PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies IHC, each developed with a ICI. We set test if next generation RNA sequencing (RNA-seq) is robust method determine mRNA expression levels furthermore, efficacy of response ICIs as compared routinely used, standardized IHC procedures.A total 209 cancer patients treated on-label by FDA-approved ICIs,...
CTLA-4 impedes the immune system's antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents - ipilimumab tremelimumab both used together with anti-PD-1/PD-L1 agents.
•VISTA expression differs among cancer types and there are diverse patterns.•High VISTA transcript correlates with high BTLA, TIM-3, TNFRSF14 expression.•High may predict poor immunotherapy survival in pancreatic patients.•Co-targeting co-expressed immunoregulatory molecules merit further investigation.•Tailored combined immune profiling warrants prospective studies. BackgroundOptimizing checkpoint inhibitor (ICI) therapy require identification of co-targetable pathways via profiling....
Background Results from epidemiologic studies on the relationship between vitamin D and breast cancer risk are inconclusive. It is possible that may be effective in reducing only of specific subtypes due to disease heterogeneity. Methods Findings In case-control case-series analyses, we examined serum concentrations 25-hydroxyvitamin (25OHD) relation prognostic characteristics, including histologic grade, estrogen receptor (ER), molecular defined by ER, progesterone (PR) HER2, among 579...
We have developed a next-generation sequencing assay to quantify biomarkers of the host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor specimens. This aims provide clinicians with comprehensive characterization immunologic microenvironment as guide for therapeutic decisions on patients solid tumors. The relies RNA-sequencing (seq) semiquantitatively measure levels 43 transcripts related anticancer responses and 11 that reflect relative abundance tumor-infiltrating...
Abstract Background Lymphocyte activation gene 3 (LAG‐3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T‐cell activation. Many clinical trials of LAG‐3 inhibitors have had modest effects, but recent data indicate the antibody relatlimab, together with nivolumab (anti‐PD‐1), provided greater benefit than alone in patients melanoma. Methods In this study, RNA expression levels 397 genes were assessed 514 diverse cancers at clinical‐grade laboratory...
Abstract Background Cancer-testis antigens (CTAs) are tumor that normally expressed in the testes but aberrantly several cancers. CTA overexpression drives metastasis and progression of lung cancer, is associated with poor prognosis. To improve cancer diagnosis, prognostic prediction, drug discovery, robust identification quantitation needed. In this study, we examined quantified co-expression CTAs to derive testis antigen burden (CTAB), a novel biomarker immunotherapy response. Methods...
// Prashant K. Singh 1 , Leah Preus 2 Qiang Hu 3 Li Yan Mark D. Long Carl Morrison 4 Mary Nesline Candace S. Johnson Shahriar Koochekpour 5 Manish Kohli 6 Song Liu Donald L. Trump 7 Lara E Sucheston-Campbell 2,* and Moray J. Campbell 1,* Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY Prevention Control, Biostatistics Bioinformatics, Pathology, Genetics, Medical Oncology, Mayo Clinic, Rochester, MN Medicine, * The authors share position as senior...
Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application these agents in the clinic challenging due to immune complexity and heterogeneity. We interrogated transcriptomics 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, TBX21) pan-cancer cohort (N = 514 patients, 30 types cancer). TPM expression was analyzed correlation with histological type,...
Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management patients with non-small cell lung cancer (NSCLC). However, practice variation can affect whether all indicated are tested. We aimed to evaluate impact common single-gene testing (SGT) on subsequent comprehensive genomic (CGP) test outcomes and results in NSCLC.
Current criteria for identifying cancer patients suitable immunotherapy with immune checkpoint blockers (ICBs) are subjective and prone to misinterpretation, as they mainly rely on the visual assessment of CD274 (best known PD-L1) expression levels by immunohistochemistry (IHC). To address this issue, we developed a RNA sequencing (RNAseq)-based approach that specifically measures abundance transcripts in formalin-fixed paraffin embedded (FFPE) specimens. Besides exhibiting superior...
Timely and accurate identification of molecular alterations in solid tumors is essential for proper management patients with advanced cancers. This has created a need rapid, scalable comprehensive genomic profiling (CGP) systems that detect an increasing number therapeutically-relevant variant types signatures. In this study, we assessed the analytical performance TruSight Oncology 500 High-Throughput assay detection somatic from formalin-fixed paraffin-embedded tissue specimens. parallel,...
Programmed cell death protein 1 (PD-1) is a critical immune checkpoint receptor and target for cancer inhibitors (ICI). We investigated PD-1 transcript expression across types its correlations to clinical outcomes. Using reference population, was calculated as percentiles in 489 of 514 patients (31 types) with advanced/metastatic disease. RNA varied within types; pancreatic liver/bile duct malignancies displayed the highest rates high (21.82% 21.05%, respectively). Elevated CTLA-4, LAG-3,...
Background: Inducible T-cell co-stimulator (ICOS) and its ligand (ICOSL) form a complex, two-faced immune machinery that can lead to both stimulation inhibition. Objective: We explored ICOS transcriptomic expression patterns their relationship with other checkpoints outcomes in patients advanced/metastatic cancers. Design: This was retrospective cohort study. Methods: RNA for quantified by sequencing stratified rank values into high (75–100 percentiles) low (0–24 percentiles). Fischer’s...
Abstract The establishment of a biorepository with linkage to clinical and epidemiologic data will provide an invaluable resource for cancer research, including studies etiology, progression, prognosis, as well development biomarkers early detection. Developing infrastructure linked clinical, pathologic, requires significant efforts in strategic planning efficient means ascertain, identify, consent participants, guidelines blood collection, processing, storage while maintaining participant...
OBJECTIVE To assess the frequency of vitamin D deficiency among men with prostate cancer, as considerable epidemiological, in vitro , vivo and clinical data support an association between cancer outcome. PATIENTS, SUBJECTS AND METHODS The study included 120 ambulatory recurrent 50 clinically localized who were evaluated serum samples assayed for 25‐OH levels. Then 100 controls (both sexes), matched age season sample, chosen from a prospective banking protocol. relationship age, body mass...
PurposeThe efficacy of checkpoint inhibitor (CPI) immunotherapy in patients with non–small cell lung cancer (NSCLC) is limited by a lack strongly predictive response markers, subjecting to potential underutilization alternative effective treatments, increased risk for futile care, and unnecessary costs. Here, we characterize the extent which basic molecular tumor-marker testing has been performed NSCLC therapy selection United States, compare medical resource utilization costs CPI-treated...
Indoleamine 2,3-dioxygenase 1 (IDO1), which catabolizes tryptophan, is a potential target to unlock the immunosuppressive tumor microenvironment. Correlations between IDO1 and immune checkpoint inhibitor (ICI) efficacy remain unclear. Herein, we investigated transcript expression across cancers clinical outcome correlations. High transcripts were more frequent in uterine (54.2%) ovarian cancer (37.2%) but varied within malignancies. RNA was associated with high of PD-L1 (immune ligand),...
Abstract Research in the last decade suggests clinical potential of circulating microRNAs whole blood as biomarkers for cancer detection. However, before applying identified clinically, biospecimen-focused research has to be performed identify possible preanalytic variables that may significantly affect levels microRNAs. In this study, using a unique resource Data Bank and BioRepository (DBBR) at Roswell Park Cancer Institute, we conducted two-step analysis internal control then study how...